Last updated: September 16, 2026
Vasopressin is a mature injectable peptide with limited active-ingredient differentiation. The strongest commercial opportunities are in excipient-controlled stability, preservative-free presentations, ready-to-use diluted bags, low-sorption containers, and hospital workflow improvements. The incumbent formulation strategy relies on acidic aqueous solutions, sodium chloride, and chlorobutanol in multidose products. A differentiated product would need to show measurable gains in stability, compatibility, safety, preparation time, or supply reliability.
What is the current vasopressin formulation strategy?
Vasopressin injection is a sterile aqueous solution of synthetic arginine vasopressin. U.S. products generally use a concentrated strength of 20 units/mL, with dilution before infusion. The formulation is administered intravenously for vasodilatory shock and, under product-specific labeling, other critical-care indications.
A representative commercial formulation contains:
| Formulation element |
Typical function |
| Vasopressin |
Synthetic peptide active ingredient |
| Water for injection |
Injectable vehicle |
| Sodium chloride |
Tonicity adjustment |
| Acetic acid or acetate-based pH adjustment |
Acidic pH control |
| Chlorobutanol hemihydrate |
Preservative in multidose presentations |
Vasostrict labeling identifies a concentrated 20 units/mL product and provides dilution instructions for preparation of lower-concentration infusions. The label also specifies storage, handling, and administration requirements that make peptide stability and container compatibility commercially relevant (Endo USA, 2023).
The excipient design has four technical objectives:
- Limit chemical degradation of vasopressin.
- Reduce adsorption to glass, plastic, and infusion-system components.
- Maintain sterility over the labeled storage period.
- Permit accurate dilution and infusion in intensive-care settings.
Vasopressin is a small nonapeptide, but its peptide structure remains sensitive to aqueous degradation, oxidation, temperature, pH, light, and surface interactions. The formulation must therefore balance chemical stability against tolerability, preservative exposure, and manufacturing complexity.
Which excipients are most important for vasopressin stability?
Acidic pH control
An acidic formulation can reduce some degradation pathways and help maintain product quality during storage. Acetic acid or an acetate system may be used to establish the target pH. A pH strategy must be validated against:
- Peptide purity and potency;
- Aggregation and degradation products;
- Container closure compatibility;
- Infusion-line compatibility;
- Local tolerability after dilution.
A formulation with a tightly controlled pH range may support a longer shelf life or improved post-dilution stability. That benefit must be demonstrated through real-time and accelerated stability studies rather than inferred from pH alone.
Sodium chloride
Sodium chloride is a conventional tonicity agent. It is inexpensive, widely accepted by regulators, and compatible with hospital compounding practices. Its main commercial limitation is that it provides little differentiation.
A low-sodium or alternative-tonicity formulation could have value in selected fluid-restricted patients, but the clinical and commercial benefit is likely narrower than the value of a ready-to-use presentation. Any change would require assessment of osmolality, vascular tolerability, dilution accuracy, and compatibility with commonly used infusion fluids.
Chlorobutanol
Chlorobutanol can support multidose vial sterility. Its presence may reduce manufacturing cost by allowing repeated vial access, but it creates a differentiation opportunity for preservative-free products.
Potential advantages of a preservative-free vasopressin presentation include:
- Reduced exposure to chlorobutanol in critically ill patients;
- Suitability for single-use systems;
- Better positioning for neonatal, pediatric, and highly sensitive populations;
- Compatibility with closed-system transfer and pharmacy automation;
- A cleaner hospital formulary profile.
The commercial case depends on whether preservative exposure is clinically meaningful at the administered dose and whether hospitals value the added cost. A preservative-free product also loses some of the convenience of a multidose vial unless it is supplied in a ready-to-use bag, syringe, or single-dose vial.
Surfactants and stabilizing excipients
Polysorbates, poloxamers, amino acids, sugars, and other peptide stabilizers could reduce adsorption or aggregation. Their use would require careful justification because each additional excipient can create new risks:
- Peroxide-mediated oxidation from degraded surfactant;
- Extractables and leachables;
- Subvisible particles;
- Infusion-line interactions;
- New toxicology requirements;
- Greater analytical burden.
A surfactant-based vasopressin product would be most defensible where data demonstrate lower surface loss, better stability after dilution, or improved compatibility with polymeric containers.
What formulation patents could protect vasopressin products?
The strongest patent claims would likely focus on formulation and presentation rather than the vasopressin molecule itself. Synthetic arginine vasopressin is an established active ingredient, so composition-of-matter protection is not commercially available for a new entrant.
Potential claim categories include:
| Patent category |
Potential protected subject matter |
| Stabilized aqueous formulation |
Defined pH, buffer, tonicity agent, and degradation limits |
| Preservative-free formulation |
Single-dose composition with specified stability |
| Ready-to-use infusion |
Diluted concentration in a defined bag or syringe |
| Container system |
Low-binding polymer, coated vial, syringe, or infusion bag |
| Post-dilution stability |
Product remaining within potency limits after defined storage |
| Manufacturing process |
Peptide purification, filling, nitrogen overlay, or lyophilization |
| Combination packaging |
Vial, diluent, transfer device, and administration set |
| Method of use |
Dosing or administration supported by a new clinical indication |
Patent strength would depend on whether the formulation produces an unexpected technical effect. A claim covering only routine excipients at conventional concentrations would face substantial obviousness risk. A stronger estate would link a defined excipient range to a measurable result, such as lower oxidation, reduced adsorption, or extended in-use stability.
How strong is the vasopressin patent estate?
The active ingredient is weakly protectable because vasopressin has long been known and is widely used as a generic injectable. Commercial exclusivity therefore depends on product-specific formulations, delivery systems, manufacturing controls, regulatory exclusivity, and supply contracts.
A new formulation patent should be evaluated against:
- Earlier vasopressin injection products;
- Peptide stabilization patents;
- Generic injectable formulation patents;
- Container and infusion-system disclosures;
- Prior art on preservative-free critical-care products;
- Published stability data for diluted vasopressin.
A patent estate based only on chlorobutanol, sodium chloride, water, and acidic pH would probably have limited blocking power unless the claims include narrow, non-obvious parameters and strong stability data.
When does vasopressin lose regulatory exclusivity?
Vasopressin has no biosimilar-style exclusivity pathway. It is a synthetic peptide drug, and follow-on products generally use the abbreviated new drug application pathway when they can meet applicable sameness and equivalence requirements.
The key U.S. milestones are:
| Event |
Commercial significance |
| Original vasopressin products |
Historical products do not create current market exclusivity |
| Vasostrict NDA approval |
FDA approval established a branded concentrated injectable product |
| Three-year exclusivity |
Any product-specific clinical investigation exclusivity would have expired years ago |
| Generic ANDA approvals |
Enabled price competition and alternative suppliers |
| Orange Book listings |
Relevant only to patents listed against the specific reference product |
| Shortage events |
Can increase value of secondary suppliers and alternate presentations |
Vasostrict was approved under NDA 204485. Its product-specific regulatory exclusivity period is no longer a meaningful barrier to generic development. Current commercial protection is more likely to arise from manufacturing scale, hospital contracts, product reliability, and formulation or device patents than from FDA exclusivity (U.S. Food and Drug Administration [FDA], 2014).
What is the Orange Book status of vasopressin?
The Orange Book analysis must be performed at the product level. The relevant questions are:
- Which product is the reference listed drug?
- Which patents, if any, are listed against that product?
- Are the patents active, expired, or removed?
- Are any patents eligible for Paragraph IV certification?
- Does the proposed generic use the same formulation and presentation?
For vasopressin, the core injectable active ingredient is old. A Paragraph IV challenge would be more likely to target a listed formulation, container, method-of-use, or manufacturing patent than the peptide itself.
A generic applicant could pursue several strategies:
- Use a formulation that avoids listed formulation claims.
- File a Paragraph IV certification against patents considered invalid or not infringed.
- Submit a section viii statement that omits a patented method of use, where legally available.
- Develop a separate presentation, such as a preservative-free vial or premixed infusion, subject to FDA requirements.
Orange Book listings should not be treated as a complete map of commercial risk. Unlisted process, device, trade-secret, and manufacturing patents can still affect supply and launch timing.
Which companies are challenging or competing with vasopressin products?
The U.S. market has included branded and generic suppliers of vasopressin injection. Competition has centered on hospital injectable manufacturers and contract manufacturing networks rather than consumer-facing brands.
Relevant competitive dimensions include:
| Competitive factor |
Commercial implication |
| 20 units/mL vial |
Established reference presentation |
| Preservative-free supply |
Differentiates from multidose products |
| Ready-to-use infusion |
Reduces pharmacy preparation |
| Reliable allocation |
Important during shortages |
| Low minimum order quantities |
Benefits smaller hospitals |
| Compatible packaging |
Supports automated dispensing and infusion systems |
| 503B outsourcing |
Can supply compounded presentations but does not equal FDA-approved generic status |
The competitive threat to a new product is greatest from established injectable manufacturers with validated sterile-fill capacity and hospital distribution contracts. A technically superior excipient system will not overcome weak supply reliability or limited wholesaler access.
What commercial opportunities exist for vasopressin excipients and delivery systems?
Ready-to-use diluted vasopressin
A premixed bag or syringe can reduce dose-calculation errors, pharmacy labor, and preparation time. The product would need a validated in-use shelf life, low adsorption to the container, and compatibility with standard infusion pumps.
This is likely the most attractive near-term opportunity because it solves a hospital workflow problem without requiring a new clinical indication.
Preservative-free single-dose products
A preservative-free vial can target hospitals seeking reduced excipient exposure or simplified medication protocols. The product may command a price premium if it improves use in pediatric, neonatal, or high-acuity settings.
Low-sorption container systems
Vasopressin can interact with surfaces and infusion materials. A low-binding polymer, coated syringe, or validated administration set could reduce delivered-dose variability, particularly at dilute concentrations.
A container patent may be more defensible than a conventional excipient patent if the sponsor can demonstrate a reproducible reduction in peptide loss.
Dual-chamber or point-of-care systems
A dual-chamber system could separate concentrated vasopressin from a diluent until administration. This approach may extend stability while reducing compounding steps. It also creates device-development, human-factors, and combination-product requirements.
Lyophilized vasopressin
A lyophilized product could improve long-term stability and reduce dependence on liquid-state controls. Its disadvantages include reconstitution steps, longer preparation time, increased manufacturing cost, and the need to prove complete and accurate reconstitution.
Lyophilization is commercially more compelling for emergency or remote-use applications than for hospitals that already use established liquid injections.
What FDA regulatory issues affect a new vasopressin formulation?
A new excipient strategy could follow different regulatory paths:
| Product concept |
Likely regulatory route |
| Same active, strength, dosage form, and formulation |
ANDA if equivalence requirements are met |
| Different excipients with equivalent performance |
ANDA may be possible, subject to FDA review |
| New delivery device or container |
ANDA or NDA depending on product differences |
| New clinical indication |
Supplemental NDA or new NDA strategy |
| Novel excipient |
Higher CMC and toxicology burden |
| Compounded ready-to-use product |
503B pathway does not provide FDA-approved-drug substitution rights |
The sponsor must address peptide identity, potency, impurities, sterility, endotoxins, particulate matter, extractables and leachables, container closure integrity, adsorption, dilution stability, and shipping excursions. FDA guidance on ANDAs and injectable products places particular weight on pharmaceutical equivalence, product quality, and container-closure controls (FDA, 2022).
What generic launch risks exist for vasopressin?
Generic entry risk is high for conventional vasopressin injection because:
- The active ingredient is established;
- The reference formulation is technically familiar;
- Clinical differentiation is limited;
- Hospital buyers are price sensitive;
- Multiple suppliers can compete once supply is qualified.
Launch risk remains meaningful because sterile injectables have manufacturing vulnerabilities. A generic may face:
- FDA inspection findings;
- Site transfer delays;
- Low commercial scale;
- Raw-material variability;
- Container or stopper changes;
- Shortage-related allocation;
- Hospital reluctance to add a low-volume supplier.
A differentiated entrant should avoid competing solely on unit price. A ready-to-use format, preservative-free product, validated low-sorption system, or superior shortage resilience offers a clearer commercial position.
What licensing deals and partnerships matter?
The most relevant partnerships are likely to involve:
- Sterile injectable contract manufacturers;
- Peptide API suppliers;
- Premixed infusion manufacturers;
- Infusion-device companies;
- Hospital group purchasing organizations;
- 503B outsourcing facilities;
- Specialty distributors.
Public FDA product information does not establish the commercial terms of supplier, manufacturing, or distribution agreements. The business value of a vasopressin license would depend on access to validated sterile capacity, formulation know-how, container technology, and hospital contracts rather than on rights to the old active ingredient.
Key Takeaways
- Vasopressin has limited active-ingredient exclusivity potential.
- The incumbent formulation uses an acidic aqueous system with sodium chloride and, in relevant presentations, chlorobutanol as a preservative.
- Preservative-free vials, ready-to-use diluted bags, low-sorption containers, and improved post-dilution stability are the clearest commercial opportunities.
- Formulation patents need defined composition ranges tied to measurable technical effects.
- Biosimilar risk is not the relevant framework; generic ANDA competition is.
- Paragraph IV risk would focus on formulation, container, method-of-use, or manufacturing patents.
- Sterile manufacturing reliability and hospital distribution are likely to matter more than conventional excipient cost.
- A product that reduces preparation time or dose variability has a stronger commercial case than a minor excipient substitution.
FAQs
Can vasopressin be formulated without chlorobutanol?
Yes. A preservative-free single-dose vial, prefilled syringe, or premixed bag can eliminate chlorobutanol, but the product must maintain sterility through its labeled use and satisfy container-closure and stability requirements.
Is vasopressin sensitive to adsorption?
Yes. Peptide loss to glass, plastics, tubing, and infusion components can matter at dilute concentrations. Container and administration-set studies should be part of development.
Is a premixed vasopressin bag likely to receive premium pricing?
It can, if the product reduces pharmacy preparation, improves dosing consistency, and maintains adequate shelf life. Hospitals will compare the premium with current compounding labor, waste, and medication-error controls.
Does a new vasopressin excipient create new clinical exclusivity?
Usually not. A new excipient system may support formulation or method-of-use patents, but it does not automatically create FDA exclusivity or block all generic versions of vasopressin injection.
Is lyophilized vasopressin commercially attractive?
It may be attractive where long-term stability, emergency storage, or remote distribution is important. For routine intensive-care use, the reconstitution burden may reduce its advantage relative to liquid or ready-to-use products.
References
-
Endo USA, Inc. (2023). Vasostrict (vasopressin injection, USP) prescribing information. U.S. Food and Drug Administration, DailyMed.
-
U.S. Food and Drug Administration. (2014). NDA 204485: Vasostrict approval package. Center for Drug Evaluation and Research.
-
U.S. Food and Drug Administration. (2022). ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of recombinant origin: Guidance for industry. Center for Drug Evaluation and Research.
-
U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary, vasopressin injection monograph. USP Convention.
